SPPI - Spectrum Pharmaceuticals, Inc.
12.80 0.00 (0.00%)
After hours: 5:02PM EST
| Previous Close | 12.72 |
| Open | 12.89 |
| Bid | 11.25 x 1800 |
| Ask | 12.92 x 1000 |
| Day's Range | 12.70 - 13.08 |
| 52 Week Range | 11.52 - 25.29 |
| Volume | 498,493 |
| Avg. Volume | 1,401,912 |
| Market Cap | 1.356B |
| Beta (3Y Monthly) | 4.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.98 |
| Earnings Date | Mar 7, 2017 - Mar 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2012-12-18 |
| 1y Target Est | 33.00 |
- Motley Fool•yesterday
Here's Why Spectrum Pharmaceuticals Rose 21.5% in November
The company announced third-quarter 2018 earnings and a pipeline update, but investors weren't happy with results from an important trial announced in early December.
- Zacks•3 days ago
Spectrum Pharma (SPPI) Down 3.7% Since Last Earnings Report: Can It Rebound?
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of SPPI earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Spectrum Pharmaceuticals Inc Earnings Call
- Business Wire•6 days ago
Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that data from the Phase 3 RECOVER clinical study was presented during the 2018 San Antonio Breast Cancer Symposium® (SABCS). ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing treatment with myelosuppressive cytotoxic chemotherapy.
- GlobeNewswire•9 days ago
Report: Exploring Fundamental Drivers Behind CVS Health, TransCanada, Nektar Therapeutics, LendingTree, Spectrum Pharmaceuticals, and TripAdvisor — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•9 days ago
Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)
HENDERSON, Nev.-- -- In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma This was the first prospective study to evaluate the effect of oral leucovorin in preventing or reducing FOLOTYN-related oral mucositis in patients with hematological malignancies, including PTCL ...
- Business Wire•12 days ago
Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data related to Peripheral T-cell Lymphoma (PTCL) and EVOMELA® (melphalan) at the 60th Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, California, from December 1-4, 2018. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
- Business Wire•29 days ago
Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors
Spectrum Pharmaceuticals Inc., (SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors. Dr. Vacirca is a practicing oncologist and the current president of the Community Oncology Alliance, an advocacy group focused on supporting community oncology clinics. Additionally, Dr. Vacirca is the medical director of the nation’s largest community oncology group purchasing organization, International Oncology Network and the CEO and managing partner at North Shore Hematology Oncology Associates.
- Zacks•last month
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3
Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.
- Zacks•last month
Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual ...
- Zacks•last month
Spectrum Pharmaceuticals (SPPI) Reports Q3 Loss, Tops Revenue Estimates
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 22.73% and 2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Spectrum Pharma: 3Q Earnings Snapshot
The Henderson, Nevada-based company said it had a loss of 66 cents per share. Losses, adjusted for non-recurring costs, were 17 cents per share. The biotechnology company posted revenue of $25.3 million ...
- Business Wire•last month
Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results
HENDERSON, Nev.-- -- Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients Spectrum has submitted a request for Breakthrough Therapy Designation for poziotinib and expects a response from the FDA by end of the year Enrollment of the EGFR, previously treated cohort in ...
- Business Wire•last month
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 London Healthcare Conference being held in London. A live webcast of Spectrum's presentation will be available at www.sppirx.com. Spectrum Pharmaceuticals is a leading biopharmaceutical company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
Market Realist•last monthVeracyte Stock Witnesses Solid Growth after Its Q3 Results
Veracyte (VCYT) stock rose 22.46% on October 30 after it released its third-quarter earnings results on October 29. On October 30, Veracyte stock closed at $11.56, a ~22.46% rise from its previous day’s close of $9.44 on October 29.
- Business Wire•last month
Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the third quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, November 8, ...
- Zacks•2 months ago
Spectrum Pharmaceuticals (SPPI) Q3 Earnings Preview: What's Shaping Up?
Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•2 months ago
Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection
• Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. “KHAPZORY is the first levoleucovorin product approved by the FDA that contains sodium in its formulation,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals.
- Benzinga•2 months ago
The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...
- Business Wire•2 months ago
Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Francois Lebel, M.D., F.R.C.P.C. as Chief Medical Officer, effective November 5, 2018. “Dr. Lebel is an accomplished leader and has deep expertise in biopharmaceuticals with an emphasis in oncology drug development,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “Given his qualifications, we believe Dr. Lebel will add significant value to Spectrum and our clinical programs.
- Zacks•2 months ago
Options Traders Expect Huge Moves in Spectrum Pharmaceuticals (SPPI) Stock
Spectrum Pharmaceuticals (SPPI) needs investors to pay close attention to the stock based on moves in the options market lately.
- Investopedia•2 months ago
Top 4 Small-Cap Stocks for 2018
Looking at growth outlooks and price targets, these four small-cap stocks could be stellar for the rest of 2018.
- Business Wire•2 months ago
Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the 2018 Cantor Global Healthcare Conference being held in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
